Measuring Fluid Flow in the Brain Using Alcohol and MRI in Healthy Participants
NCT ID: NCT04608292
Last Updated: 2024-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
10 participants
INTERVENTIONAL
2026-01-31
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that such an investigation can be developed using magnetic resonance spectroscopy to give a quantitative measure of ISF flow, using spectroscopy of ethanol as a dynamic marker of interstitial fluid. Beneficially, the approach is non-invasive. This pilot project aims to develop this technique with proof of concept in healthy volunteers (males in the age range of 20-75).
This pilot project aims to develop the technique, demonstrating its ability to detect ISF flow and potential differences in rates among healthy volunteers. Success at this stage will give rise to this technique being extended to studies involving individuals with various forms of intracranial pathology for comparison with values seen in healthy individuals, with the ultimate goal of it providing a measure of diagnostic significance in multiple clinical scenarios.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MR Evaluation of Cerebrospinal Fluid (CSF) Dynamics
NCT04099823
Assessment of Cerebrospinal Fluid Flow Related Disorders Using a Phase-contrast Magnetic Resonance Imaging Technique.
NCT03656016
PET Measures of CSF Clearance in Preclinical Alzheimer's Disease
NCT03663387
High-field Brain Magnetic Resonance Spectroscopy
NCT02053701
Non-Heme Iron Load Quantification in the Brain - MRI of Patients With Stroke
NCT01829386
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intracranial interstitial fluid (ISF) flow is crucial for adequate clearance of extracellular waste products from the brain parenchyma. Recent demonstrations have shown that its deficiency leads to their accumulation in neurodegenerative disorders. The hypothesis of this project is MRS and/or MTI can be used to give a quantitative measure of intracranial interstitial fluid flow.
Goals:
The primary goal is to provide a quantitative measure of ISF flow rate through the brain parenchyma. This will be performed by making multiple measurements of the characteristic ethanol peak at different time points with MRS or ethanol-related decreases in water saturation signal in MTI, following its ingestion. This will allow the transit of ethanol, which is equal to the transit of ISF, to be obtained and reported using common transport parameters such as time-to-peak (TTP) and mean transit time (MTT).
Secondary objectives include determining a range of values that may be considered normal ranges for ISF flow rates in healthy individuals. This will be helpful in future experiments when such values will be compared with rates measuring for individuals with various different types of intracranial pathology.
INVESTIGATION STUDY DESIGN:
This pilot project will be experimental with the aim of determining the best quantitative criteria from ethanol MRS or MTI labeling of intracranial ISF flow data to give a reliable clearance metric. To achieve this, the initial proof of concept study will involve 10 healthy male volunteers between the ages of 20-75 undergoing the ethanol-MRS or MTI protocol. This work will be quantitative in nature, since discrete MR signals will be measured and analyzed.
Data Collection Study participants will be required to have fasted a minimum of 6 hours prior to initiating the experiment and refrained from alcohol ingestion for 12 hours. A quick screen will be performed by a research team member of the participant's medications, alcohol consumption, and any neurological conditions prior to moving forward with the examination to verify all volunteers meet all inclusion criteria for the study.
Data will be acquired using either magnetic resonance spectroscopy (MRS), magnetic resonance spectroscopic imaging (MRSI), or magnetization transfer imaging (MTI). A relatively short acquisition (5-7 minutes) will be repeated to acquire a time course for ethanol transit through the brain.
Each study participant will undergo pre-ethanol ingestion MR acquisition. The volunteer will then be given an ethanol-containing beverage. The ethanol content will be approximately 0.5 g/kg, mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink as done previously in other human ethanol MRS experiments (7). The drink must be consumed within 5 minutes and may be provided through clear plastic tubing so the subject does not have to be removed from the scanner. Blood alcohol concentration (BAC) levels for this work are not expected to exceed 0.05%, considered a low level, at the end of the experiment.
After consuming the ethanol-containing beverage, scout images will be acquired again to re-localize the voxels for each subsequent spectral image if study participants need to be placed back in the MR scanner (i.e., did not ingest ethanol through tubing). MRS, MRSI, or MTI will be performed at \~5-7 minutes/spectrum or image, repeating the process continuously for 60-90 minutes. During the scanning, the patient may be asked to breathe through the ClearMate (CM), a specially designed, MR-compatible non-rebreathing circuit that provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
After the final acquisition, the patient will be taken to a supervised area where he/she will remain until blood ethanol levels are registered below 0.05% via a standard breathalyzer test. Once the participant has met this requirement and state that they feel safe to leave the premises, they will be free to go within the recommendations of the study and their participation considered to be complete. Breath sampling will be performed at 30-minute intervals if it is still high.
Finally, since the most accurate way to assess the blood alcohol kinetics is by making comparisons of arterial and venous blood levels, peripheral arterial lines will be inserted (by a Sunnybrook staff anesthesiologist) in a few select study participants. Periodic arterial blood samples from these individuals will be measured for the blood alcohol content and compared with the values for blood samples drawn concurrently from the peripheral intravenous line.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single-voxel MRS
MRS
Single-voxel MRS
Diagnostic test is a single voxel MRS scan
Alcohol ingestion
Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
Multi-voxel MRSI
MRSI
Multi-voxel MRSI
Diagnostic test is a multi-voxel MRS imaging scan
Alcohol ingestion
Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
Magnetization Transfer Imaging
MTI
Magnetization Transfer Imaging
Diagnostic test is a set of magnetic transfer weighted images
Alcohol ingestion
Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
Single-voxel MRS + ClearMate
MRS+CM
Single-voxel MRS
Diagnostic test is a single voxel MRS scan
Alcohol ingestion
Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
ClearMate
Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
Multi-voxel MRSI + ClearMate
MRSI+CM
Multi-voxel MRSI
Diagnostic test is a multi-voxel MRS imaging scan
Alcohol ingestion
Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
ClearMate
Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
Magnetization Transfer Imaging + ClearMate
MTI+CM
Magnetization Transfer Imaging
Diagnostic test is a set of magnetic transfer weighted images
Alcohol ingestion
Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
ClearMate
Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
Single-voxel MRS + ClearMate + Blood Sampling
MRS+CM+B
Single-voxel MRS
Diagnostic test is a single voxel MRS scan
Alcohol ingestion
Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
ClearMate
Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
Blood sampling
Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.
Multi-voxel MRSI + ClearMate + Blood Sampling
MRSI+CM+B
Multi-voxel MRSI
Diagnostic test is a multi-voxel MRS imaging scan
Alcohol ingestion
Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
ClearMate
Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
Blood sampling
Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.
Magnetization Transfer Imaging + ClearMate + Blood Sampling
MTI+CM+B
Magnetization Transfer Imaging
Diagnostic test is a set of magnetic transfer weighted images
Alcohol ingestion
Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
ClearMate
Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
Blood sampling
Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Single-voxel MRS
Diagnostic test is a single voxel MRS scan
Multi-voxel MRSI
Diagnostic test is a multi-voxel MRS imaging scan
Magnetization Transfer Imaging
Diagnostic test is a set of magnetic transfer weighted images
Alcohol ingestion
Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
ClearMate
Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
Blood sampling
Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Low consumer of ethanol (less than 6 drinks per week where a drink is 1 oz of distilled spirits, 6 oz wine, 12 oz beer)
Exclusion Criteria
* History of alcohol or substance abuse
* History of liver pathology
* Currently taking medication such as metronidazole which could induce a disulfiram reaction with ethanol
20 Years
75 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Health Network, Toronto
OTHER
Sunnybrook Health Sciences Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Greg J Stanisz, PhD
Role: PRINCIPAL_INVESTIGATOR
Sunnybrook Research Institute
David Mikulis, MD
Role: PRINCIPAL_INVESTIGATOR
Krembil Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sunnybrook Research Institute
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
023-2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.